Literature DB >> 27333447

3D tissue-engineered bone marrow: what does this mean for the treatment of multiple myeloma?

Pilar de la Puente1, Abdel Kareem Azab1.   

Abstract

Entities:  

Keywords:  3DTEBM; bone marrow; drug resistance; multiple myeloma; tissue-engineered cultures; tumor microenvironment

Mesh：

Year:  2016        PMID： 27333447      PMCID： PMC7175478          DOI： 10.2217/fon-2016-0057

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


× No keyword cloud information.
  20 in total

1.  The development of a model for the homing of multiple myeloma cells to human bone marrow.

Authors:  M Urashima; B P Chen; S Chen; G S Pinkus; R T Bronson; D A Dedera; Y Hoshi; G Teoh; A Ogata; S P Treon; D Chauhan; K C Anderson
Journal:  Blood       Date:  1997-07-15       Impact factor: 22.113

2.  Autologous fibrin scaffolds cultured dermal fibroblasts and enriched with encapsulated bFGF for tissue engineering.

Authors:  Pilar de la Puente; Dolores Ludeña; Ana Fernández; Jose L Aranda; Gonzalo Varela; Javier Iglesias
Journal:  J Biomed Mater Res A       Date:  2011-09-27       Impact factor: 4.396

Review 3.  Multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2004-10-28       Impact factor: 91.245

4.  Absence of renal lesions in C57BL/KaLwRij mice with advanced myeloma due to 5T2MM cells.

Authors:  Hélène Libouban; Céline Onno; Florence Pascaretti-Grizon; Yves Gallois; Marie-Françoise Moreau; Michel F Baslé; Daniel Chappard
Journal:  Leuk Res       Date:  2006-06-30       Impact factor: 3.156

5.  BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.

Authors:  Aldo M Roccaro; Antonio Sacco; Patricia Maiso; Abdel Kareem Azab; Yu-Tzu Tai; Michaela Reagan; Feda Azab; Ludmila M Flores; Federico Campigotto; Edie Weller; Kenneth C Anderson; David T Scadden; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

6.  RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma.

Authors:  Abdel Kareem Azab; Feda Azab; Simona Blotta; Costas M Pitsillides; Brian Thompson; Judith M Runnels; Aldo M Roccaro; Hai T Ngo; Molly R Melhem; Antonio Sacco; Xiaoying Jia; Kenneth C Anderson; Charles P Lin; Barrett J Rollins; Irene M Ghobrial
Journal:  Blood       Date:  2009-05-14       Impact factor: 22.113

Review 7.  Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.

Authors:  Teru Hideshima; Constantine Mitsiades; Giovanni Tonon; Paul G Richardson; Kenneth C Anderson
Journal:  Nat Rev Cancer       Date:  2007-08       Impact factor: 60.716

Review 8.  Contemporary drug therapies for multiple myeloma.

Authors:  P de la Puente; A K Azab
Journal:  Drugs Today (Barc)       Date:  2013-09       Impact factor: 2.245

9.  A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells.

Authors:  T Calimeri; E Battista; F Conforti; P Neri; M T Di Martino; M Rossi; U Foresta; E Piro; F Ferrara; A Amorosi; N Bahlis; K C Anderson; N Munshi; P Tagliaferri; F Causa; P Tassone
Journal:  Leukemia       Date:  2011-01-14       Impact factor: 11.528

Review 10.  Molecularly targeted therapies in multiple myeloma.

Authors:  Pilar de la Puente; Barbara Muz; Feda Azab; Micah Luderer; Abdel Kareem Azab
Journal:  Leuk Res Treatment       Date:  2014-04-16
View more
  4 in total

1.  Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.

Authors:  Pilar de la Puente; Micah J Luderer; Cinzia Federico; Abbey Jin; Rebecca C Gilson; Christopher Egbulefu; Kinan Alhallak; Shruti Shah; Barbara Muz; Jennifer Sun; Justin King; Daniel Kohnen; Noha Nabil Salama; Samuel Achilefu; Ravi Vij; Abdel Kareem Azab
Journal:  J Control Release       Date:  2017-11-28       Impact factor: 9.776

2.  Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.

Authors:  Daniela Belloni; Silvia Heltai; Maurilio Ponzoni; Antonello Villa; Barbara Vergani; Lorenza Pecciarini; Magda Marcatti; Stefania Girlanda; Giovanni Tonon; Fabio Ciceri; Federico Caligaris-Cappio; Marina Ferrarini; Elisabetta Ferrero
Journal:  Haematologica       Date:  2018-01-11       Impact factor: 9.941

Review 3.  In Vitro Modeling of Non-Solid Tumors: How Far Can Tissue Engineering Go?

Authors:  Sandra Clara-Trujillo; Gloria Gallego Ferrer; José Luis Gómez Ribelles
Journal:  Int J Mol Sci       Date:  2020-08-11       Impact factor: 5.923

4.  A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma.

Authors:  Kinan Alhallak; Amanda Jeske; Pilar de la Puente; Jennifer Sun; Mark Fiala; Feda Azab; Barbara Muz; Ilyas Sahin; Ravi Vij; John F DiPersio; Abdel Kareem Azab
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.